Alternatives for the treatment of infections caused by ESKAPE pathogens

What is known and Objective The widespread use of antibiotics as therapeutic agents caused an increase of multidrug resistant bacteria (MDR) appearance. Regarding MDRs, we highlight the Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacy and therapeutics 2020-08, Vol.45 (4), p.863-873
Hauptverfasser: Rosa, Taciéli Fagundes, Coelho, Silvana Silveira, Foletto, Vitória Segabinazzi, Bottega, Angelita, Serafin, Marissa Bolson, Machado, Catrine de Souza, Franco, Laísa Nunes, Paula, Bruno Rafael, Hörner, Rosmari
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:What is known and Objective The widespread use of antibiotics as therapeutic agents caused an increase of multidrug resistant bacteria (MDR) appearance. Regarding MDRs, we highlight the Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.., which are the ESKAPE group. Comment New treatment alternatives for infections caused by ESKAPE are under current scientific research. The main suggestions are the use of actinomycetes that produce promising substances with antibiotic activity, the synergistic effect between antimicrobials and peptides, photoinactivation, peptide rich in cationic histidine, association of new antimicrobials; besides the repositioning of drugs already approved for the treatment of other diseases. What is New and Conclusion These selected studies showed that researchers from many countries are focused on the development of effective alternative strategies for the treatment of infections caused by these microorganisms. We present a selection of scientific research demonstrating some of these alternatives for treating ESKAPE pathogens.
ISSN:0269-4727
1365-2710
DOI:10.1111/jcpt.13149